Search results
YOUR HEALTH: Why some kidney cancer patients are living longer
WAFB Baton Rouge· 1 day agoKidney cancer is among the 10 most common cancers in both men and women. A decade ago, advanced...
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 day agoWe'd also like to congratulate ArsenalBio, who in April announced the first patient dosed in a Phase...
Afinitor interactions: Other medications, alcohol, and more
Medical News Today· 6 days agoAfinitor has interactions with some other drugs and certain supplements. Before you start treatment...
Q1 2024 Abcellera Biologics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 1 day agoWe'd also like to congratulate our single bio, who in April, announced the first patient dosed in a Phase one two trial for AB. 21 hundred, which is in development as a treatment< ...
Nexavar Dosage: Form, Strength, How to Take, and More
Healthline· 3 days agoNexavar (sorafenib) is a prescription drug used to treat liver, kidney, and thyroid cancers. Nexavar belongs to a group of drugs called kinase inhibitors and contains the active ingredient sorafenib ...
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 22 hours agoAbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript May 7, 2024 AbCellera...
High Response Rates With Gene Therapies for BCG-Unresponsive Bladder Cancer
MedPage Today· 5 days agoThree-fourths of patients had complete responses, which proved to be durable in most cases
New York State Common Retirement Fund Sells 5,141 Shares of Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 6 days agoNew York State Common Retirement Fund trimmed its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 0.5% during the 4th quarter, according to the company in ...
HC Wainwright Reaffirms Buy Rating for Exelixis (NASDAQ:EXEL)
ETF DAILY NEWS· 3 days agoHC Wainwright reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report sent to investors on Friday, Benzinga reports. Several other equities analysts ...
Exelixis (NASDAQ:EXEL) Earns “Outperform” Rating from William Blair
ETF DAILY NEWS· 5 days agoWilliam Blair reaffirmed their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report published on Wednesday, RTT News reports. Barclays lowered Exelixis from an overweight ...
